Margin recovery the focus as TOPCon ramp hits stride
After Q1's brutal 85% PAT collapse despite 38% revenue growth, Q2 FY27 is a litmus test for whether the new TOPCon plant is normalizing or headwinds persist. The 9 GW cell plant coming online in December could be the rerating catalyst.
The setup: margin trajectory is everything
Q1 FY27 delivered a textbook bull-trap print: revenue surged 38% YoY to ₹1,563 Cr on the back of the new module plant commissioned in July 2026, but net profit collapsed 85% to just ₹19.8 Cr. The stock has paid the price, down 66% from its all-time high. The market's question for Q2 is simple: was that profit crater a one-time commissioning hit, or is the new TOPCon capacity fundamentally margin-dilutive? The answer will drive sentiment into the critical December quarter, when the 9 GW cell plant begins first production.
~₹1,500–1,600 Cr
On-plan from Q1 run-rate; 11+ GW order book supports volumes
Stabilization key
Q1 ₹19.8 Cr was crash; Q2 FY26 was ₹128 Cr. Margin recovery would signal ramp is normalizing
FY27 guidance 1.7x FY26
CFO said per-unit outcome expected to match Q2/Q4 FY26; suggests ramp headwinds near-term
What a strong quarter looks like: Revenue tracking Q1 (₹1,500+ Cr), PAT stabilizing to double-digit ₹20–30+ Cr range (signal that commissioning costs are normalizing), management reaffirming the 9 GW cell plant timeline for December production, and order book commentary staying upbeat (more wins in the pipeline). What a weak quarter looks like: Revenue dipping below Q1, PAT staying crushed at single-digit Cr (signal that margin pressure is structural, not transient), any pushback on cell plant timeline, or guidance walk-backs on FY27 EBITDA.
On track for full-year?
Management guided FY27 EBITDA to be 1.7x FY26 in absolute terms, with per-unit economics expected to match Q2 and Q4 of FY26 (the pre-TOPCon, pre-margin-pressure period). The fact that Q1 delivered ₹1,563 Cr in revenue but only ₹19.8 Cr in profit suggests the company is in heavy investment/ramp mode. If Q2 shows profit stabilization—even if still below Q2 FY26's ₹128 Cr—it would suggest management's guidance is on track. A deeper profit dip would raise questions about execution risk or market oversupply.
What the Street says
Recent filings & corporate activity
1 · Order wins accelerating
October 2026 saw a 289.87 MWp supply order from NLC India for TOPCon modules (Oct 27). September saw a 400 MW agri-solar module order (Sep 28) and a 124 MW supply contract for Andhra Pradesh (Sep 11). These signal solid downstream demand despite the stock's weakness, and underscore the company's pivot to higher-margin TOPCon product.
2 · Cell plant ramp (Dec target unshaken)
Management reaffirmed on October 23 that the 9 GW N-type TOPCon cell plant at Gangaikondan is on schedule to produce its first cells in December 2026. This is a key inflection point: own cell supply could improve margins and reduce outside cell-procurement costs as volumes scale.
3 · Senior sales executive departure
EVP Sales & BD Rony Banerjee resigned on September 29, with a Chief Business Officer appointed. A management shuffle at the sales head during a ramp suggests either internal restructuring or execution pressure—worth monitoring for commentary on the call.
4 · Ownership and insider activity
No recent promoter pledges or insider selling. Promoter holding stable at 63%. FII increased 43 bps QoQ to 3.37% (suggesting some tactical interest), while DII dipped 77 bps to 4.03%. Bulk deals in August 2026 were inter-dealer trades with no insider red flags.
Numbers to watch on results day
Revenue
~₹1,500–1,600 Cr
Volume trajectory; should track Q1 if order book flows
₹1,563 Cr
Net profit
₹30–50 Cr (est.)
Margin stabilization is THE swing factor; below ₹20 Cr = missed guidance risk
₹19.8 Cr (−85% YoY)
EBITDA
Track FY27 1.7x guidance
Should show positive EBITDA trajectory if on-plan
Not disclosed
Order book
Track new wins
11+ GW post-July orders; confirm if momentum sustains
Not specified Q1
Vikram Solar is at an inflection: the ₹1,563 Cr Q1 revenue print proved demand is there, but the 85% PAT collapse raised the bar for Q2 to show meaningful margin recovery. The 9 GW cell plant—first production in December—is the bigger story; own-supply economics could re-rate the stock if execution stays on track. Management's FY27 EBITDA guidance (1.7x FY26) suggests conviction in the ramp, but investors want to see profit turning a corner, not just top-line growth.
Three things to listen for on the call: (1) Is the Q1 margin squeeze a commissioning effect or a market headwind? (2) December cell plant timeline—any slippage or cost changes? (3) What's the path to ₹128 Cr+ PAT levels seen in prior mature quarters? A solid profit print and a clean cell-plant commentary could pivot sentiment; a disappointing PAT would deepen the discount.
Informational and educational content only. Not investment advice.